Clene Australia

Clene is a clinical-stage biopharmaceutical company pioneering the development of clean-surfaced nanotechnology (CSN) therapeutics for neurodegenerative diseases. The company's proprietary platform utilizes electro-crystal-chemistry to produce stable, concentrated nanocrystal suspensions that act as nanocatalysts to enhance cellular energy production and reduce oxidative stress. Its lead asset, CNM-Au8, is a gold nanocrystal suspension currently in Phase 3 development for amyotrophic lateral sclerosis (ALS) and Phase 2 for multiple sclerosis (MS) and Parkinson’s disease. Clene also maintains a pipeline of other metal-based nanotherapeutics for infectious diseases and oncology. Headquartered in Salt Lake City, the company operates its own cGMP manufacturing facility in Maryland and maintains an active presence in Australia through its subsidiary, Clene Australia Pty Ltd, to support clinical research.